

## Multiple myeloma days 31 August - 01 September 2017

### CLL/MCL days 02 September 2017

31 August 2017 9.00 – 17.00

Multiple myeloma pathogenesis (role of CD38 and examples of patient cytometry with CD38 – MM diagnostics)

Novel myeloma guidelines – what's new?

MM diagnostics

- Diagnostic for new disease (laboratory approaches with examples)
- Relapse diagnostic (laboratory approaches with examples)

MM treatment approaches – in trials

- ASCT candidates
- Non-ASCT candidates (monoclonal antibodies for relapse – daratumumab as example)
- High-risk patients
- Double refractory patients – what are the more preferable approaches?

Patients Portraits – in routine practice what are the common treatments approaches?

Patient for first line

Patient for 2-nd line and so on

(Both for ASCT candidates and non-ASCT candidates)

01 September 2017

First part of day (01 September 2017) 9:00 – 13:00

Multiple myeloma – continuation of patients' discussion

What are the most common issues in patient treatment?

Infusion reactions for monoclonal antibodies (daratumumab as example)

Blood typing issues in anti-CD38 antibodies

Response assessment

Adverse events

Second part of day (01 September 2017) 14:00 – 17:00

Visit to clinic for physicians

02 September 2017 9:00 – 17:00

CLL biology (genetic factors, high risk disease)

Diagnostic and prognostic work-up of CLL

CLL – common treatment approaches (latest guidelines)

First line CLL treatment

Relapse CLL treatment

Most effective treatment approaches (in accordance with the clinical trials) – patients portraits based on real patients

MCL biology

Diagnostic and prognostic work-up of MCL

Current treatment approaches in MCL

New treatment strategies in MCL

MCL – common treatment approaches (latest guidelines)

Relapse MCL treatment

MCL treatment approaches (in accordance with the clinical trials) – patients portraits based on real patients